$1.61 Billion is the total value of Eventide Asset Management's 126 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BLUE | BLUEBIRD BIO INC | $59,847,000 | +15.6% | 569,700 | 0.0% | 3.73% | +8.7% | |
| LOW | LOWES COS INC | $43,804,000 | -5.7% | 565,000 | 0.0% | 2.73% | -11.3% | |
| CELG | CELGENE CORP | $39,649,000 | +4.4% | 305,300 | 0.0% | 2.47% | -1.9% | |
| STKL | SUNOPTA INC | $39,647,000 | +46.8% | 3,887,000 | 0.0% | 2.47% | +38.0% | |
| STLD | STEEL DYNAMICS INC | $34,020,000 | +3.0% | 950,000 | 0.0% | 2.12% | -3.1% | |
| WBC | WABCO HLDGS INC | $32,592,000 | +8.6% | 255,600 | 0.0% | 2.03% | +2.1% | |
| SPLK | SPLUNK INC | $28,445,000 | -8.7% | 500,000 | 0.0% | 1.77% | -14.1% | |
| CYBR | CYBERARK SOFTWARE LTD | $27,473,000 | -1.8% | 550,000 | 0.0% | 1.71% | -7.7% | |
| SGEN | SEATTLE GENETICS INC | $27,164,000 | -17.7% | 525,000 | 0.0% | 1.69% | -22.6% | |
| LEA | LEAR CORP | $26,143,000 | +0.4% | 184,000 | 0.0% | 1.63% | -5.6% | |
| ASML | ASML HOLDING N V | $26,062,000 | -1.9% | 200,000 | 0.0% | 1.62% | -7.7% | |
| SNA | SNAP ON INC | $25,280,000 | -6.3% | 160,000 | 0.0% | 1.57% | -11.9% | |
| CRUS | CIRRUS LOGIC INC | $23,206,000 | +3.3% | 370,000 | 0.0% | 1.44% | -2.8% | |
| ARW | ARROW ELECTRS INC | $23,134,000 | +6.8% | 295,000 | 0.0% | 1.44% | +0.4% | |
| XLRN | ACCELERON PHARMA INC | $19,872,000 | +14.8% | 653,900 | 0.0% | 1.24% | +7.9% | |
| INST | INSTRUCTURE INC | $19,765,000 | +26.1% | 670,000 | 0.0% | 1.23% | +18.6% | |
| TWLO | TWILIO INCcl a | $19,358,000 | +0.8% | 665,000 | 0.0% | 1.20% | -5.2% | |
| IPHI | INPHI CORP | $19,037,000 | -29.7% | 555,000 | 0.0% | 1.18% | -33.9% | |
| FPRX | FIVE PRIME THERAPEUTICS INC | $18,096,000 | -16.7% | 601,000 | 0.0% | 1.13% | -21.6% | |
| VCYT | VERACYTE INC | $17,772,000 | -9.3% | 2,133,500 | 0.0% | 1.11% | -14.7% | |
| AGIO | AGIOS PHARMACEUTICALS INC | $15,476,000 | -11.9% | 300,800 | 0.0% | 0.96% | -17.1% | |
| VMC | VULCAN MATLS CO | $13,935,000 | +5.1% | 110,000 | 0.0% | 0.87% | -1.0% | |
| BPMC | BLUEPRINT MEDICINES CORP | $13,428,000 | +26.7% | 265,000 | 0.0% | 0.84% | +19.1% | |
| STML | STEMLINE THERAPEUTICS INC | $9,995,000 | +7.6% | 1,086,400 | 0.0% | 0.62% | +1.1% | |
| ACAD | ACADIA PHARMACEUTICALS INC | $9,335,000 | -18.9% | 334,700 | 0.0% | 0.58% | -23.8% | |
| ONCE | SPARK THERAPEUTICS INC | $8,961,000 | +12.0% | 150,000 | 0.0% | 0.56% | +5.3% | |
| PANW | PALO ALTO NETWORKS INC | $8,698,000 | +18.8% | 65,000 | 0.0% | 0.54% | +11.8% | |
| WVE | WAVE LIFE SCIENCES LTD | $8,063,000 | -32.4% | 433,500 | 0.0% | 0.50% | -36.4% | |
| XNCR | XENCOR INC | $7,262,000 | -11.7% | 344,000 | 0.0% | 0.45% | -17.1% | |
| CERN | CERNER CORP | $7,192,000 | +12.9% | 108,200 | 0.0% | 0.45% | +6.2% | |
| ALNY | ALNYLAM PHARMACEUTICALS INC | $7,178,000 | +55.6% | 90,000 | 0.0% | 0.45% | +46.6% | |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $6,812,000 | +3.5% | 75,000 | 0.0% | 0.42% | -2.8% | |
| PRTA | PROTHENA CORP PLC | $6,494,000 | -3.0% | 120,000 | 0.0% | 0.40% | -8.8% | |
| SAGE | SAGE THERAPEUTICS INC | $6,451,000 | +12.1% | 81,000 | 0.0% | 0.40% | +5.5% | |
| EXR | EXTRA SPACE STORAGE INC | $6,357,000 | +4.8% | 81,500 | 0.0% | 0.40% | -1.2% | |
| GWPH | GW PHARMACEUTICALS PLCads | $6,366,000 | -17.1% | 63,500 | 0.0% | 0.40% | -22.0% | |
| NBIX | NEUROCRINE BIOSCIENCES INC | $5,750,000 | +6.2% | 125,000 | 0.0% | 0.36% | 0.0% | |
| RARE | ULTRAGENYX PHARMACEUTICAL IN | $5,428,000 | -8.4% | 87,400 | 0.0% | 0.34% | -13.8% | |
| INCY | INCYTE CORP | $5,036,000 | -5.8% | 40,000 | 0.0% | 0.31% | -11.3% | |
| RGEN | REPLIGEN CORP | $4,558,000 | +17.7% | 110,000 | 0.0% | 0.28% | +10.9% | |
| VRTX | VERTEX PHARMACEUTICALS INC | $4,459,000 | +17.8% | 34,600 | 0.0% | 0.28% | +10.8% | |
| ATRC | ATRICURE INC | $4,365,000 | +26.6% | 180,000 | 0.0% | 0.27% | +19.3% | |
| BOLD | AUDENTES THERAPEUTICS INC | $4,304,000 | +12.3% | 225,000 | 0.0% | 0.27% | +5.5% | |
| TTPH | TETRAPHASE PHARMACEUTICALS I | $4,278,000 | -22.4% | 600,000 | 0.0% | 0.27% | -27.1% | |
| EPZM | EPIZYME INC | $4,153,000 | -11.9% | 275,000 | 0.0% | 0.26% | -17.0% | |
| GLPG | GALAPAGOS NVspon adr | $3,979,000 | -11.2% | 52,000 | 0.0% | 0.25% | -16.5% | |
| ACRS | ACLARIS THERAPEUTICS INC | $3,797,000 | -9.1% | 140,000 | 0.0% | 0.24% | -14.5% | |
| TSRO | TESARO INC | $3,636,000 | -9.1% | 26,000 | 0.0% | 0.23% | -14.7% | |
| NTUS | NATUS MEDICAL INC DEL | $2,798,000 | -5.0% | 75,000 | 0.0% | 0.17% | -10.8% | |
| VYGR | VOYAGER THERAPEUTICS INC | $2,688,000 | -32.3% | 300,000 | 0.0% | 0.17% | -36.5% | |
| MGNX | MACROGENICS INC | $2,574,000 | -5.9% | 147,000 | 0.0% | 0.16% | -11.6% | |
| AQXP | AQUINOX PHARMACEUTICALS INC | $2,462,000 | -15.7% | 175,000 | 0.0% | 0.15% | -20.7% | |
| SYRS | SYROS PHARMACEUTICALS INC | $2,414,000 | +1.0% | 150,000 | 0.0% | 0.15% | -5.1% | |
| CTMX | CYTOMX THERAPEUTICS INC | $2,325,000 | -10.3% | 150,000 | 0.0% | 0.14% | -15.7% | |
| TCON | TRACON PHARMACEUTICALS INC | $2,160,000 | -36.0% | 900,000 | 0.0% | 0.13% | -39.9% | |
| CHRS | COHERUS BIOSCIENCES INC | $2,081,000 | -32.1% | 145,000 | 0.0% | 0.13% | -36.0% | |
| CDTX | CIDARA THERAPEUTICS INC | $1,980,000 | -3.8% | 264,000 | 0.0% | 0.12% | -9.6% | |
| HTGC | HERCULES CAPITAL INC | $1,324,000 | -12.5% | 100,000 | 0.0% | 0.08% | -18.0% | |
| ESSA PHARMA INC | $1,308,000 | -82.4% | 2,719,410 | 0.0% | 0.08% | -83.5% | ||
| DRNA | DICERNA PHARMACEUTICALS INC | $1,195,000 | -6.8% | 377,000 | 0.0% | 0.07% | -12.9% | |
| VTR | VENTAS INC | $486,000 | +6.8% | 7,000 | 0.0% | 0.03% | 0.0% | |
| LPT | LIBERTY PPTY TRsh ben int | $489,000 | +5.6% | 12,000 | 0.0% | 0.03% | -3.2% | |
| WELL | WELLTOWER INC | $412,000 | +5.6% | 5,500 | 0.0% | 0.03% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
About Eventide Asset Management
Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.
The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.
The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.
Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.
Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LOWES COS INC | 40 | Q3 2023 | 3.2% |
| PALO ALTO NETWORKS INC | 40 | Q3 2023 | 3.6% |
| ASML HOLDINGS NV | 40 | Q3 2023 | 1.9% |
| NEUROCRINE BIOSCIENCES INC | 40 | Q3 2023 | 1.1% |
| REPLIGEN CORP | 40 | Q3 2023 | 0.5% |
| VERACYTE INC | 38 | Q3 2023 | 1.5% |
| LAM RESEARCH CORP | 35 | Q3 2023 | 3.4% |
| XPO LOGISTICS INC | 34 | Q1 2023 | 3.8% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.6% |
| MAGNA INTL INC | 33 | Q4 2021 | 2.5% |
View Eventide Asset Management's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | February 14, 2023 | 2,589,778 | 3.7% |
| ESSA Pharma Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Freeline Therapeutics Holdings plc | February 14, 2023 | 5,920,765 | 9.1% |
| KnowBe4, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Praxis Precision Medicines, Inc. | February 14, 2023 | 3,518,062 | 7.5% |
| Prometheus Biosciences, Inc. | February 14, 2023 | 1,032,938 | 2.2% |
| SUTRO BIOPHARMA, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| Vital Farms, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Zymeworks Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Entasis Therapeutics Holdings Inc. | February 14, 2022 | 590,602 | 1.2% |
View Eventide Asset Management's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Eventide Asset Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.